Vaxcyte (PCVX) Share-based Compensation (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Share-based Compensation data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 75.71% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $15.0 million, a 79.31% decrease from a year earlier, with the FY2025 full-year figure at $11.0 million, down 87.04% from the prior year.
• Share-based Compensation for Q1 2026 stood at $9.3 million, up from -$91.9 million in the prior quarter.
• Over the last five years, Share-based Compensation for PCVX reached as high as $96.8 million in Q3 2025 and fell as low as -$91.9 million in Q4 2025.
• Historically, Share-based Compensation has averaged $6.1 million across 5 years, with a median of $4.1 million in 2022.
• Across the five-year window, Share-based Compensation plunged 749.65% in 2022 and soared 86478.31% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$15.8 million in 2022, then sank by 99.85% to -$31.5 million in 2023, then soared by 327.09% to $71.6 million in 2024, then plunged by 228.27% to -$91.9 million in 2025, then surged by 110.12% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $9.3 million in Q1 2026, -$91.9 million in Q4 2025, and $96.8 million in Q3 2025.